Skip to main content
Erschienen in: European Radiology 8/2019

21.01.2019 | Nuclear Medicine

Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer

verfasst von: Antoine Girard, Mathieu Rouanne, Sarah Taconet, Camélia Radulescu, Yann Neuzillet, Astrid Girma, Aurélie Beaufrere, Thierry Lebret, Elise Le Stanc, Jean-François Grellier

Erschienen in: European Radiology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Preoperative 18F-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is controversial to assess lymph node (LN) staging in patients with invasive bladder cancer. We proposed to use the maximum standardized uptake value (SUVmax) associated with axial-based LN size to improve the detection of regional LN metastasis.

Methods

From May 2015 to May 2017, we prospectively included patients with urothelial bladder cancer who underwent radical cystectomy with extended pelvic LN dissection. All patients underwent preoperative 18F-FDG PET/CT staging before surgery. The gold standard comparator was the pathological examination of resected LNs. The data were reported on a regional per area- and patient-based model according to SUVmax values and axial-based LN size criteria.

Results

In total, 1012 LNs were identified in 61 patients with clinically localized invasive bladder cancer who underwent radical cystectomy and extended pelvic LN dissection. Loco-regional involvement of 24 LN areas was confirmed in 17 patients. In per area analysis, diagnostic accuracy of PET/CT and CT alone were respectively 84% and 78% (p = 0.039). On patient-based analysis, combined PET/CT correctly classified pelvic LN status in 5/61 (+ 8%) additional patients using optimal thresholds compared to CT alone, with accuracies of 82% and 74%, respectively (p = 0.13).

Conclusion

Combining SUVmax and axial-based LN size criteria using 18F-FDG PET/CT improved the diagnostic accuracy for preoperative LN staging in patients with invasive bladder cancer, in per area analysis.

Key Points

Combining metabolical and morphological features using18F-FDG PET/CT improves the detection of malignant lymph node in patients with bladder cancer.
18 F-FDG PET/CT may help for initial staging of patients with muscle invasive bladder cancer.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMed
2.
3.
Zurück zum Zitat Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108CrossRefPubMed Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108CrossRefPubMed
4.
5.
Zurück zum Zitat Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5):1039–1047CrossRefPubMed Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5):1039–1047CrossRefPubMed
6.
Zurück zum Zitat Apolo AB, Riches J, Schöder H et al (2010) Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 28(25):3973–3978CrossRefPubMedPubMedCentral Apolo AB, Riches J, Schöder H et al (2010) Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 28(25):3973–3978CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S (2013) Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int 112(6):729–734CrossRefPubMed Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S (2013) Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int 112(6):729–734CrossRefPubMed
8.
Zurück zum Zitat Yang Z, Cheng J, Pan L et al (2012) Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer? Ann Nucl Med 26(7):571–577CrossRefPubMed Yang Z, Cheng J, Pan L et al (2012) Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer? Ann Nucl Med 26(7):571–577CrossRefPubMed
9.
Zurück zum Zitat Alfred Witjes J, Lebret T, Compérat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475CrossRefPubMed Alfred Witjes J, Lebret T, Compérat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475CrossRefPubMed
10.
Zurück zum Zitat Pichler R, De Zordo T, Fritz J et al (2017) Pelvic lymph node staging by combined18F-FDG-PET/CT imaging in bladder cancer prior to radical cystectomy. Clin Genitourin Cancer 15(3):e387–e395CrossRefPubMed Pichler R, De Zordo T, Fritz J et al (2017) Pelvic lymph node staging by combined18F-FDG-PET/CT imaging in bladder cancer prior to radical cystectomy. Clin Genitourin Cancer 15(3):e387–e395CrossRefPubMed
11.
Zurück zum Zitat Hitier-Berthault M, Ansquer C, Branchereau J et al (2013) 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol 20(8):788–796CrossRefPubMed Hitier-Berthault M, Ansquer C, Branchereau J et al (2013) 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol 20(8):788–796CrossRefPubMed
12.
Zurück zum Zitat Goodfellow H, Viney Z, Hughes P et al (2014) Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 114(3):389–395PubMed Goodfellow H, Viney Z, Hughes P et al (2014) Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 114(3):389–395PubMed
13.
Zurück zum Zitat Rouanne M, Girma A, Neuzillet Y et al (2014) Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Eur J Surg Oncol 40(12):1724–1730CrossRefPubMed Rouanne M, Girma A, Neuzillet Y et al (2014) Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Eur J Surg Oncol 40(12):1724–1730CrossRefPubMed
14.
Zurück zum Zitat Jeong IG, Hong S, You D, Hong JH, Ahn H, Kim CS (2015) FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol 22(9):3150–3156 Jeong IG, Hong S, You D, Hong JH, Ahn H, Kim CS (2015) FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol 22(9):3150–3156
15.
Zurück zum Zitat Swinnen G, Maes A, Pottel H et al (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57(4):641–647CrossRefPubMed Swinnen G, Maes A, Pottel H et al (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57(4):641–647CrossRefPubMed
16.
Zurück zum Zitat Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of [18F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27(26):4314–4320CrossRefPubMedPubMedCentral Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of [18F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27(26):4314–4320CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Uttam M, Pravin N, Anish B, Nandita K, Arup M (2016) Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer? Int Braz J Urol 42(2):234–241CrossRefPubMedPubMedCentral Uttam M, Pravin N, Anish B, Nandita K, Arup M (2016) Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer? Int Braz J Urol 42(2):234–241CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Aljabery F, Lindblom G, Skoog S et al (2015) PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer. BMC Urol 15:87CrossRefPubMedPubMedCentral Aljabery F, Lindblom G, Skoog S et al (2015) PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer. BMC Urol 15:87CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Soubra A, Hayward D, Dahm P et al (2016) The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol 34(9):1229–1237CrossRefPubMed Soubra A, Hayward D, Dahm P et al (2016) The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol 34(9):1229–1237CrossRefPubMed
20.
Zurück zum Zitat Vind-Kezunovic S, Bouchelouche K, Ipsen P, Høyer S, Bell C, Bjerggaard Jensen J (2017) Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and18F-fluorodeoxyglucose positron emission tomography/computed tomography: results from a high-volume centre including long-term follow-up. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.06.005 Vind-Kezunovic S, Bouchelouche K, Ipsen P, Høyer S, Bell C, Bjerggaard Jensen J (2017) Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and18F-fluorodeoxyglucose positron emission tomography/computed tomography: results from a high-volume centre including long-term follow-up. Eur Urol Focus. https://​doi.​org/​10.​1016/​j.​euf.​2017.​06.​005
21.
Zurück zum Zitat ADASP Committee. The Association of Directors of Anatomic and Surgical Pathology (2001) ADASP recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Mod Pathol 14(6):629–632 ADASP Committee. The Association of Directors of Anatomic and Surgical Pathology (2001) ADASP recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Mod Pathol 14(6):629–632
23.
Zurück zum Zitat Nguyen HT, Shah ZK, Mortazavi A et al (2017) Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study. Eur Radiol 27(5):2146–2152CrossRefPubMed Nguyen HT, Shah ZK, Mortazavi A et al (2017) Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study. Eur Radiol 27(5):2146–2152CrossRefPubMed
24.
Zurück zum Zitat Lee M, Shin SJ, Oh YT et al (2017) Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion. Eur Radiol 27(9):3752–3758CrossRefPubMed Lee M, Shin SJ, Oh YT et al (2017) Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion. Eur Radiol 27(9):3752–3758CrossRefPubMed
25.
Zurück zum Zitat Panebianco V, De Berardinis E, Barchetti G et al (2017) An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 27(9):3759–3766CrossRefPubMed Panebianco V, De Berardinis E, Barchetti G et al (2017) An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 27(9):3759–3766CrossRefPubMed
26.
Zurück zum Zitat Derlin T, Weiberg D, von Klot C et al (2016) 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 26:4345–4353CrossRefPubMed Derlin T, Weiberg D, von Klot C et al (2016) 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 26:4345–4353CrossRefPubMed
28.
Zurück zum Zitat Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM (2017) Systematic review of immune checkpoint inhibition in urological cancers. Eur Urol 72(3):411–423CrossRefPubMed Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM (2017) Systematic review of immune checkpoint inhibition in urological cancers. Eur Urol 72(3):411–423CrossRefPubMed
Metadaten
Titel
Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer
verfasst von
Antoine Girard
Mathieu Rouanne
Sarah Taconet
Camélia Radulescu
Yann Neuzillet
Astrid Girma
Aurélie Beaufrere
Thierry Lebret
Elise Le Stanc
Jean-François Grellier
Publikationsdatum
21.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 8/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5959-0

Weitere Artikel der Ausgabe 8/2019

European Radiology 8/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.